Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 81 to 90 of 480 total matches.

Molnupiravir for Treatment of COVID-19

   
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022  (Issue 1642)
of progressing to severe disease, including hospitalization or death (see Table 1), and for whom alternative ...
The investigational oral antiviral drug molnupiravir (Merck/Ridgeback Biotherapeutics) was granted an FDA Emergency Use Authorization (EUA) on December 23, 2021 for treatment of mild to moderate COVID-19 in outpatients ≥18 years old who are at high risk of progressing to severe disease, including hospitalization or death (see Table 1), and for whom alternative treatment options are not available or clinically appropriate. Paxlovid (Pfizer), nirmatrelvir copackaged with ritonavir, was granted an EUA on December 22, 2021. The IV antiviral drug remdesivir (Veklury) was approved by the FDA in...
Med Lett Drugs Ther. 2022 Jan 24;64(1642):10-1 | Show Introduction Hide Introduction

Oxymetazoline Cream (Rhofade) for Rosacea

   
The Medical Letter on Drugs and Therapeutics • May 22, 2017  (Issue 1521)
-adrenergic receptor agonist oxymetazoline as a 1% cream (Rhofade – Allergan) for topical treatment of persistent ...
The FDA has approved the selective alpha1A-adrenergic receptor agonist oxymetazoline as a 1% cream (Rhofade – Allergan) for topical treatment of persistent facial erythema of rosacea in adults. Brimonidine, a selective alpha2-adrenergic receptor agonist, was approved in 2013 as a 0.33% gel (Mirvaso) for the same indication. Like Mirvaso, Rhofade is not indicated for treatment of inflammatory lesions of rosacea. Oxymetazoline has been available over the counter for many years as a nasal decongestant spray (Afrin, and others).
Med Lett Drugs Ther. 2017 May 22;59(1521):84-6 | Show Introduction Hide Introduction

Durysta - A Bimatoprost Implant for Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020  (Issue 1603)
inhibitor, a selective alpha2-agonist, or the Rho kinase inhibitor netarsudil (Rhopressa)1 can be added ...
The FDA has approved an intracameral implant containing the prostaglandin analog bimatoprost (Durysta – Allergan) for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Bimatoprost is also available in 0.01% (Lumigan) and 0.03% (generics) ophthalmic solutions for the same indication and in a 0.03% solution (Latisse, and generics) for eyelash enhancement. Durysta is the first ocular implant to become available in the US for treatment of glaucoma.
Med Lett Drugs Ther. 2020 Jul 27;62(1603):116-7 | Show Introduction Hide Introduction

Desmopressin (Nocdurna and Noctiva) for Nocturnal Polyuria

   
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019  (Issue 1568)
. Pharmacologic treatment has included off-label use of timed loop diuretics and desmopressin.1,2 Table 1 ...
The FDA has approved a sublingual tablet (Nocdurna – Ferring) and a nasal spray (Noctiva – Avadel) formulation of desmopressin acetate for treatment of nocturia due to nocturnal polyuria in adults who wake up ≥2 times per night to void. Nocdurna and Noctiva are the first two products to be approved in the US for this indication. Higher-strength nasal spray and oral tablet formulations of desmopressin (DDAVP, and others) have been available for years for treatment of diabetes insipidus and primary nocturnal enuresis (bedwetting in children). In 2007, the indication for primary nocturnal...
Med Lett Drugs Ther. 2019 Mar 25;61(1568):46-8 | Show Introduction Hide Introduction

In Brief: Neuropsychiatric Events with Montelukast

   
The Medical Letter on Drugs and Therapeutics • May 04, 2020  (Issue 1597)
of suicidal behavior and other serious neuropsychiatric events associated with its use.1 Montelukast has ...
The FDA is requiring stronger warnings in the labeling of the leukotriene receptor antagonist montelukast (Singulair, and generics) about the risk of suicidal behavior and other serious neuropsychiatric events associated with its use.
Med Lett Drugs Ther. 2020 May 4;62(1597):65 | Show Introduction Hide Introduction

In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
-19 vaccine to include adolescents 12-15 years old.1 The vaccine has been authorized for use ...
On May 10, 2021, the FDA expanded its Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine to include adolescents 12-15 years old.1The vaccine has been authorized for use in persons ≥16 years old since December 2020.
Med Lett Drugs Ther. 2021 May 31;63(1625):81 | Show Introduction Hide Introduction

A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine

   
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021  (Issue 1640)
it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.1 ...
The FDA has approved Trudhesa (Impel Neuropharma), a new dihydroergotamine nasal spray product, for acute treatment of migraine with or without aura in adults. Another dihydroergotamine nasal spray (Migranal, and generics) has been available for many years for the same indication.
Med Lett Drugs Ther. 2021 Dec 27;63(1640):204-7 | Show Introduction Hide Introduction

Istradefylline (Nourianz) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020  (Issue 1591)
, or a monoamine oxidase type B (MAO-B) inhibitor.1,2 A subcutaneous formulation of the nonergot dopamine agonist ...
The FDA has approved istradefylline (Nourianz — Kyowa Kirin), an oral adenosine A2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD) who experience "off" episodes. Istradefylline is the first adenosine A2A receptor antagonist to be approved in the US; it has been available in Japan since 2013.
Med Lett Drugs Ther. 2020 Feb 10;62(1591):20-3 | Show Introduction Hide Introduction

Guselkumab (Tremfya) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Nov 06, 2017  (Issue 1533)
release of pro-inflammatory cytokines (such as IL-17A) and chemokines. Table 1. Pharmacology Class IL ...
The FDA has approved the interleukin (IL)-23 blocker guselkumab (Tremfya – Janssen) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Guselkumab is the first selective IL-23 blocker to become available in the US.
Med Lett Drugs Ther. 2017 Nov 6;59(1533):179-80 | Show Introduction Hide Introduction

Juluca - A Two-Drug Complete Regimen for HIV (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018  (Issue 1561)
-1 infection who do not have a history of treatment failure or known substitutions associated ...
The FDA has approved Juluca (ViiV Healthcare/Janssen), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay) and the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (Edurant), as a once-daily complete regimen for treatment of adults with HIV-1 infection who do not have a history of treatment failure or known substitutions associated with resistance to either drug and have been taking a stable suppressive antiretroviral regimen for ≥6 months. Dolutegravir/rilpivirine is the first complete regimen to be approved for treatment of...
Med Lett Drugs Ther. 2018 Dec 3;60(1561):e202-204 | Show Introduction Hide Introduction